My Cart [ 0 ]
Home > Cell Biology > Stable Cell Lines > Lucentis Biosimilar Cell Line

Lucentis Biosimilar Cell Line

Ranibizumab, Anti-VEGF-A Humanized Monoclonal Antibody (Fab)

Catalog No. Product Name Size List Price (US$) Quantity
C005 Lucentis Biosimilar Stable Cell Line 1 package Request

The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.

Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.

C005: Lucentis Biosimilar Cell Line (E. coli)

The yield of Lucentis biosimilar from E.coli was above 36 mg/L in a 7.5 liter manufacturing.

The Lucentis biosimilar cell line alone can be transfered alone or together with the technology of process development and/or antibody purification.

Syd Labs also provides the following VEGF-A antibody biosimilar stable cell line:
Avastin Biosimilar Stable Cell Line (complete antibody produced in CHO)

Related Links

See our Privacy Policy